Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14740062 | 0.89 | CYP1A2 (0.65) | CYP1A2CYP2C9CYP2C19SMN1; SMN2MAPK1 | |
| SCHEMBL14739556 | 0.85 | CYP1A2 (0.53) | CYP1A2CYP2C9CYP2C19SMN1; SMN2MAPK1 | |
| SCHEMBL10675936 | 0.83 | CYP1A2 (1.00) | CYP1A2CYP2C9CYP2C19SMN1; SMN2MAPK1 | |
| SCHEMBL570612 | 0.82 | MAPK1 (0.75) | CYP1A2CYP2C9CYP2C19SMN1; SMN2MAPK1 | |
| SCHEMBL2829842 | 0.82 | MAPK1 (1.00) | CYP1A2CYP2C9CYP2C19SMN1; SMN2MAPK1 | |
| SCHEMBL14739951 | 0.81 | NPC1 (0.48) | CYP1A2CYP2C9CYP2C19SMN1; SMN2MAPK1 | |
| SCHEMBL9500170 | 0.81 | CYP1A2 (0.86) | CYP1A2CYP2C9CYP2C19SMN1; SMN2MAPK1 | |
| SCHEMBL14739782 | 0.80 | DPP4 (0.45) | CYP1A2CYP2C9CYP2C19SMN1; SMN2MAPK1 | |
| SCHEMBL10675727 | 0.80 | CYP1A2 (0.84) | CYP1A2CYP2C9CYP2C19SMN1; SMN2MAPK1 | |
| SCHEMBL14710313 | 0.79 | CYP1A2 (0.82) | CYP1A2CYP2C9CYP2C19SMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9593109-B2 | Bicyclic agonists of GPR131 and uses thereof | CYMABAY THERAPEUTICS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593109-B2 | Bicyclic agonists of GPR131 and uses thereof | CYMABAY THERAPEUTICS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| WO-2013032939-A1 | BICYCLIC AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20130059845-A1 | BICYCLIC AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. | 2013-03-07 | — | — | US | disclosed |
| US-20130059845-A1 | BICYCLIC AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. | 2013-03-07 | — | — | US | disclosed |
| WO-2013032939-A1 | BICYCLIC AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059845-A1 | BICYCLIC AGONISTS OF GPR131 AND USES THEREOF | GPR119, GPR88, GPR3 | CYP1A2 1164/4885CYP2C9 3119/4885CYP2C19 1864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.